# Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

> **NCT03887702** · PHASE3 · TERMINATED · sponsor: **SWOG Cancer Research Network** · enrollment: 4 (actual)

## Conditions studied

- Hepatitis B Infection
- Malignant Solid Neoplasm

## Interventions

- **OTHER:** Best Practice
- **DRUG:** Entecavir
- **DRUG:** Tenofovir Alafenamide
- **DRUG:** Tenofovir Disoproxil Fumarate

## Key facts

- **NCT ID:** NCT03887702
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-17
- **Primary completion:** 2022-12-20
- **Final completion:** 2022-12-20
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** inability to accrue
- **Last updated:** 2024-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03887702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03887702, "Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03887702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*